Page 28 - Binding Affinity News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A group of researchers at Kannur University reviewed selected papers and in silico work on potential drug leads that could be used to manage COVID-19.

Researchers in the UK and Austria have identified a novel class of antibodies that is highly effective at neutralizing the original strain of severe acute respiratory syndrome (SARS-CoV-2) and maintaining blocking activity against certain viral variants that have emerged.

A team of scientists from the United States has recently engineered a pre-existing anti-severe acute respiratory syndrome coronavirus (SARS-CoV) neutralizing antibody to increase its binding affinity for the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The engineered antibody demonstrates high potency in neutralizing SARS-CoV-2 and preventing infection in animals.

Researchers characterize a large set of therapeutic antibodies against SARS-CoV-2 variants A team of scientists from A-Alpha Bio., USA, has recently conducted a large-scale screening of 33 therapeutic antibodies to examine their binding affinity to a number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The team analyzed the impact of potential mutations in the spike receptor-binding domain (RBD) on antibody efficacy. The study is currently available on the Background Therapeutic monoclonal antibodies developed against SARS-CoV-2 have shown significant efficacy in ...

The SARS-CoV-2 B.1.1.7 variant, also called the UK variant, was identified in London as well as in Southeast and East of England in December 2020. Since its emergence, the UK variant has undergone several mutations that have been said to have altered its infectivity and transmissibility in the community. The B.1.1.7 variant is defined by 17 mutations, several of which are located in the SARS-CoV-2 spike protein that mediates viral attachment and entry into human cells.